Revised forecast
Fiscal year ending March 2027 · Full yearThe bar length represents the relative magnitude of change, based on the item that changed the most in this document.
For the fiscal year ending March 2027, profit is expected to increase due to higher revenue driven by sustained growth in the gastrointestinal endoscopy solutions business in major regions, higher gross profit, the gradual decline of one-off factors, structural efficiency improvements under the new operating model, and disciplined cost management.
Costs of approximately ¥26.9 billion associated with measures to transform the organizational structure and optimize positions; impairment losses of approximately ¥1.6 billion on intangible assets in the Surgical Interventions business; and increases in impairment losses on development assets of approximately ¥3.4 billion in the Gastrointestinal Endoscopy Solutions business and approximately ¥2.5 billion in the Surgical Interventions business
| Item | Details |
|---|---|
| Net Sales | Not disclosed → 1,076,000～1,055,000 |
| Operating profit | Not disclosed → 155,500～136,500 |
| Profit attributable to owners of the parent | Not disclosed → 109,000～95,500 |
| Net income per share | Not disclosed → 102.24～89.58 |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Previous-period results | Revenue ¥1,010,676 million, operating profit ¥97,120 million, profit before tax ¥93,994 million, profit for the period attributable to owners of the parent ¥68,172 million, basic earnings per share ¥61.32 |
| Reason for the revision | For the fiscal year ending March 2027, profit is expected to increase due to higher revenue driven by sustained growth in the gastrointestinal endoscopy solutions business in major regions, higher gross profit, the gradual decline of one-off factors, structural efficiency improvements under the new operating model, and disciplined cost management. |
| Details and amount of extraordinary loss | Costs of approximately ¥26.9 billion associated with measures to transform the organizational structure and optimize positions; impairment losses of approximately ¥1.6 billion on intangible assets in the Surgical Interventions business; and increases in impairment losses on development assets of approximately ¥3.4 billion in the Gastrointestinal Endoscopy Solutions business and approximately ¥2.5 billion in the Surgical Interventions business |
| Dividend forecast revision | The annual dividend for the fiscal year ending March 2027 is planned to be ¥30, comprising a year-end dividend of ¥30, unchanged from the current fiscal year. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.For the fiscal year ended March 2026, profit was pressured by a higher cost ratio due to U.S. tariffs and an unfavorable sales mix, costs associated with changes to the organizational structure and position optimization, expenses related to the investment in Swan EndoSurgical, and impairment losses on intangible and development assets. For the fiscal year ending March 2027, profit is expected to increase on higher revenue and gross profit, the gradual decline of one-off factors, structural efficiency improvements, and disciplined cost management.